Home › Funds › Motley Fool Wealth Management, LLC › BMRN
Motley Fool Wealth Management, LLC position in BMRN
BIOMARIN PHARMACEUTICAL INC COM · Health Care
Motley Fool Wealth Management, LLC reported holding 3,533 shares of BMRN (BIOMARIN PHARMACEUTICAL INC COM) in its Q2 2026 13F filing — a position valued at US$202K, representing 3.07% of its reported portfolio and ranking #17 among its reported holdings. Motley Fool Wealth Management, LLC has disclosed BMRN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Motley Fool Wealth Management, LLC's BMRN position evolved
Motley Fool Wealth Management, LLC first disclosed a stake in BMRN in Q3 2023 at 488,956 shares (US$43.3M). The position peaked in Q4 2023 at 470,289 shares, worth US$45.4M. Across 12 filings, Motley Fool Wealth Management, LLC increased the stake 1 time(s), trimmed it 9 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 3,533 shares valued at US$202K — a reduction of -244,344 shares quarter over quarter.. Notable position changes include a 36% increase in Q2 2025 (shares fell 1% over the following quarter), a 25% trim in Q1 2026 (shares rose 1% over the following quarter), a 99% trim in Q2 2026 (shares rose 5% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 488.96K | $43.26M | New |
| Q4 2023 | 470.29K | $45.43M | Reduce |
| Q1 2024 | 458.74K | $40.07M | Reduce |
| Q2 2024 | 445.70K | $36.71M | Reduce |
| Q3 2024 | 424.60K | $29.84M | Reduce |
| Q4 2024 | 347.73K | $22.73M | Reduce |
| Q1 2025 | 348.98K | $24.67M | Hold |
| Q2 2025 | 475.95K | $26.16M | Add |
| Q3 2025 | 415.88K | $22.52M | Reduce |
| Q4 2025 | 330.85K | $19.66M | Reduce |
| Q1 2026 | 247.88K | $14.00M | Reduce |
| Q2 2026 | 3.53K | $202.16K | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BMRN and 13F data
BMRN (BIOMARIN PHARMACEUTICAL INC COM) is a Health Care company. 27 other funds we track also report a position in BMRN — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$812.0M), Viking Global Investors (US$435.8M), VIKING GLOBAL INVESTORS LP (US$435.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BMRN
- PRIMECAP MANAGEMENT CO/CA/ 14.19M sh · $811.96M · Q2 2026
- Viking Global Investors 7.62M sh · $435.82M · Q2 2026
- VIKING GLOBAL INVESTORS LP 7.62M sh · $435.82M · Q2 2026
- Vestal Point Capital, LP 6.03M sh · $344.75M · Q2 2026
- Deep Track Capital, LP 3.31M sh · $189.25M · Q2 2026
- TENOR CAPITAL MANAGEMENT Co., L.P. 111.50M sh · $108.89M · Q2 2026
More on Motley Fool Wealth Management, LLC
FAQ
How long has Motley Fool Wealth Management, LLC held BMRN?
Motley Fool Wealth Management, LLC has disclosed BMRN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Motley Fool Wealth Management, LLC's current position in BMRN?
As of Q2 2026, Motley Fool Wealth Management, LLC holds 3.53K shares of BMRN (BIOMARIN PHARMACEUTICAL INC COM), valued at $202.16K, representing 3.07% of its reported portfolio and ranking #17.
Has Motley Fool Wealth Management, LLC been buying or selling BMRN?
In the latest 13F filing (Q2 2026), Motley Fool Wealth Management, LLC reduced its position in BMRN. The position peaked in Q4 2023 at 470.29K shares.
Which other funds hold BMRN?
Other major institutional holders of BMRN include PRIMECAP MANAGEMENT CO/CA/, Viking Global Investors, VIKING GLOBAL INVESTORS LP, among 27 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.